Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 4/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443537 | 0.94 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL30142450 | 0.90 | ALDH1A1 (0.53) | KDM4EALDH1A1SMN1; SMN2LTA4HHTT | |
| SCHEMBL701311 | 0.90 | ALDH1A1 (0.53) | KDM4EALDH1A1SMN1; SMN2LTA4HHTT | |
| SCHEMBL4091425 | 0.84 | HRH3 (0.48) | KDM4EALDH1A1SMN1; SMN2LTA4HHRH3 | |
| SCHEMBL21636709 | 0.84 | ALDH1A1 (0.58) | KDM4EALDH1A1SMN1; SMN2HTTTSHR | |
| SCHEMBL871366 | 0.84 | LTA4H (0.54) | KDM4EALDH1A1LTA4HHRH3 | |
| SCHEMBL27474134 | 0.84 | HRH3 (0.45) | ESR1HRH3 | |
| SCHEMBL18124821 | 0.84 | LIPG (0.50) | MAPK1 | |
| SCHEMBL585479 | 0.83 | PSMB1 (0.55) | KDM4ELTA4HHRH3 | |
| SCHEMBL2801619 | 0.81 | LPL (0.51) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | KDM4E 3895/4885ALDH1A1 128/4885SMN1; SMN2 1943/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | KDM4E 3895/4885ALDH1A1 128/4885SMN1; SMN2 1943/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | KDM4E 4822/4885ALDH1A1 100/4885SMN1; SMN2 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.